Overview

Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure

Status:
Unknown status
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
Purpose: This study evaluates the subacute effect of levosimendan infusion on exercise capacity and exercise hemodynamics compared with placebo in patients with advanced chronic heart failure. Hypothesis: Treatment with 6 hours infusion of levosimendan compared with placebo improves exercise capacity and exercise hemodynamics evaluated by change in CO/PCWP. Design: The study is a prospective multi-center, double-blinded, placebo controlled randomized study. 42 consecutive patients who meet the eligibility criteria will be enrolled.
Phase:
Phase 4
Details
Lead Sponsor:
Finn Gustafsson
Collaborator:
Orion Corporation, Orion Pharma
Treatments:
Simendan